NcXHF

CHEAH, OKI, AND FANALE
eral T cell lymphoma. Results of the randomized phase III trial
GOELAMS-LTP95. Br J Haematol. 2010;151:159-166.
5. Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of
patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer
Center experience. Cancer. 2005;103:2091-2098.
6. Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose
CHOP/ESHAP regimen) followed by autologous stem-cell transplantation
in previously untreated patients with peripheral T-cell lymphoma.
Ann Oncol. 2008;19:958-963.
7. Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas
in a large US multicenter cohort: prognostication in the modern
era including impact of frontline therapy. Ann Oncol. 2014;25:2211-2217.
8. Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of
mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell
lymphoma treated in studies of the German High-Grade Non-Hodgkin
Lymphoma Study Group. Blood. 2010;116:3418-3425.
9. Ellin F, Landström J, Jerkeman M, et al. Real-world data on prognostic
factors and treatment in peripheral T-cell lymphomas: a study from the
Swedish Lymphoma Registry. Blood. 2014;124:1570-1577.
10. Corradini P, Vitolo U, Rambaldi A, et al. Intensifıed chemoimmunotherapy
with or without stem cell transplantation in newly diagnosed
patients with peripheral T-cell lymphoma. Leukemia. 2014;28:
1885-1891.
11. d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stemcell
transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin
Oncol. 2012;30:3093-3099.
12. Nickelsen M, Ziepert M, Zeynalova S, et al. High-dose CHOP plus etoposide
(MegaCHOEP) in T-cell lymphoma: a comparative analysis of
patients treated within trials of the German High-Grade Non-Hodgkin
Lymphoma Study Group (DSHNHL). Ann Oncol. 2009;20:1977-1984.
13. Reimer P, Rüdiger T, Geissinger E, et al. Autologous stem-cell transplantation
as fırst-line therapy in peripheral T-cell lymphomas: results
of a prospective multicenter study. J Clin Oncol. 2009;27:106-113.
14. Rodriguez J, Conde E, Gutiérrez A, et al. Frontline autologous stem cell
transplantation in high-risk peripheral T-cell lymphoma: a prospective
study from The Gel-Tamo Study Group. Eur J Haematol. 2007;79:32-38.
15. Smith SM, Burns LJ, van Besien K, et al. Hematopoietic cell transplantation
for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol.
2013;31:3100-3109.
16. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral
T-cell lymphoma after fırst relapse or progression: spectrum of disease
and rare long-term survivors. J Clin Oncol. 2013;31:1970-1976.
17. Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective
open-label, phase II trial of bendamustine in refractory or relapsed
T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;31:104-110.
18. Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in
pretreated T-cell lymphoma patients: evaluation of the long-term outcome.
Ann Oncol. 2010;21:860-863.
19. Zinzani PL, Magagnoli M, Bendandi M, et al. Therapy with gemcitabine
in pretreated peripheral T-cell lymphoma patients. Ann Oncol. 1998;9:
1351-1353.
20. Frei E 3rd, Karon M, Levin RH, et al. The effectiveness of combinations
of antileukemic agents in inducing and maintaining remission in children
with acute leukemia. Blood. 1965;26:642-656.
21. Izbicka E, Diaz A, Streeper R, et al. Distinct mechanistic activity profıle
of pralatrexate in comparison to other antifolates in in vitro and in vivo
models of human cancers. Cancer Chemother Pharmacol. 2009;64:993-
999.
22. O’Connor OA, Hamlin PA, Portlock C, et al. Pralatrexate, a novel class
of antifol with high affınity for the reduced folate carrier-type 1, produces
marked complete and durable remissions in a diversity of chemotherapy
refractory cases of T-cell lymphoma. Br J Haematol. 2007;139:
425-428.
23. O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with
relapsed or refractory peripheral T-cell lymphoma: results from the pivotal
PROPEL study. J Clin Oncol. 2011;29:1182-1189.
24. Koch E, Story SK, Geskin LJ. Preemptive leucovorin administration
minimizes pralatrexate toxicity without sacrifıcing effıcacy. Leuk Lymphoma.
2013;54:2448-2451.
25. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer
treatment. J Clin Invest. 2014;124:30-39.
26. Dickinson M, Cheah C, Prince HM. Current Epigenetic Therapy for
T-Cell Lymphoma. In Foss F (ed). T-Cell Lymphomas, Contemporary
Hematology. New York, NY: Humana Press. 2013;279-296.
27. Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients
with peripheral T-cell lymphoma. Blood. 2011;117:5827-5834.
28. Coiffıer B, Pro B, Prince HM, et al. Results from a pivotal, open-label,
phase II study of romidepsin in relapsed or refractory peripheral T-cell
lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631-636.
29. Coiffıer B, Pro B, Prince HM, et al. Romidepsin for the treatment of
relapsed/refractory peripheral T-cell lymphoma: pivotal study update
demonstrates durable responses. J Hematol Oncol. 2014;7:11.
30. Chihara D, Oki Y, Fayad L, et al. Phase I study of romidepsin in combination
with ICE (ifosfamide, carboplatin and etoposide) in patients with
relapsed or refractory peripheral T-cell lymphoma [abstract]. Blood.
2014;124:1748.
31. O’Connor OA, Masszi T, Savage KJ, et al. Belinostat, a novel panhistone
deacetylase inhibitor (HDACi), in relapsed or refractory peripheral
T-cell lymphoma (R/R PTCL): results from the BELIEF trial.
J Clin Oncol. 2013; 31 (suppl; abstr 8507).
32. Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of
SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic
large cell lymphoma. Br J Haematol. 2009;146:171-179.
33. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-
CD30-monomethyl auristatin E conjugate with potent and selective antitumor
activity. Blood. 2003;102:1458-1465.
34. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing
study of brentuximab vedotin in patients with relapsed/refractory
CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18:
248-255.
35. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-
35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:
1812-1821.
36. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients
with relapsed or refractory systemic anaplastic large-cell lymphoma:
results of a phase II study. J Clin Oncol. 2012;30:2190-2196.
37. Ansell SM. Brentuximab vedotin. Blood. 2014;124:3197-3200.
38. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed
T-cell lymphomas with single-agent brentuximab vedotin.
Blood. 2014;123:3095-3100.
39. Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression
among hematologic neoplasms: implications for the use of alemtuzumab
(CAMPATH-1H). Clin Cancer Res. 2006;12:7174-7179.
40. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab
(anti-CD52 monoclonal antibody) therapy for patients with relapsed or
chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;
103:2920-2924.
41. Zinzani PL, Alinari L, Tani M, et al. Preliminary observations of a phase
II study of reduced-dose alemtuzumab treatment in patients with pretreated
T-cell lymphoma. Haematologica. 2005;90:702-703.
42. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-
0761, a defucosylated humanized anti-CCR4 antibody, in relapsed pa-
e476
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook